Pathology of liver metastases

Cancer Control

Volumn 13, Issue 1, 2006, Pages 13-26

  Centeno, Barbara A ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MCC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; CYTOKERATIN; PEROXIDASE; STEM CELL FACTOR RECEPTOR; VIMENTIN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADRENAL CORTEX CARCINOMA; ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; COLON CARCINOMA; DISEASE MARKER; ENDOSCOPIC BIOPSY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEIOMYOSARCOMA; LIVER BIOPSY; LIVER CARCINOMA; LIVER METASTASIS; LUNG CARCINOMA; LYMPHOMA; MELANOMA; MICROARRAY ANALYSIS; MUCINOUS CARCINOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEEDLE BIOPSY; NEUROENDOCRINE TUMOR; PANCREAS CARCINOMA; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SAMPLING; SARCOMA; SIGNET RING CARCINOMA; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; TISSUE PREPARATION; UROGENITAL TRACT CANCER;

EID: 33644659339     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300103     Document Type: Review

References (101)

1. Abbruzzese JL, Abbruzzese MC, Lenzi R, et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13:2094-2103.
2. Axe SR, Erozan YS, Ermatinger SV. Fine-needle aspiration of the liver. A comparison of smear and rinse preparations in the detection of cancer. Am J Clin Pathol. 1986;86:281-285.
3. Stewart CJ, Coldewey J, Stewart IS. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol. 2002;55:93-97.
4. Jacobsen GK, Gammelgaard J, Fuglo M. Coarse needle biopsy versus fine needle aspiration biopsy in the diagnosis of focal lesions of the liver: ultrasonically guided needle biopsy in suspected hepatic malignancy. Acta Cytol. 1983;27:152-156.
5. Bedenne L, Mottot C, Courtois B, et al. Is the Tru-Cut needle more efficient than the fine needle in the diagnosis of hepatic lesions? Comparative study of 45 echography-guided punctures. Gastroenterol Clin Biol [French]. 1990;14:62-66.
6. Livraghi T, Sangalli G, Giordano F, et al. Fine aspiration versus fine cutting needle, and comparison between smear cytology, inclusion cytology and microhistology in abdominal lesions. Tumori. 1988;74:361-364.
7. Cochand-Priollet B, Chagnon S, Ferrand J, et al. Comparison of cytologic examination of smears and histologic examination of tissue cores obtained by fine needle aspiration biopsy of the liver. Acta Cytol. 1987;31:476-480.
8. Lin BP, Chu JM, Rose RA. Ultrasound guided fine needle biopsy of the liver for cytology and histology. Australas Radiol. 1991;35:33-37.
9. Solmi L, Muratori R, Bacchini P, et al. Comparison between echoguided fine-needle aspiration cytology and microhistology in diagnosing pancreatic masses. Surg Endosc. 1992;6:222-224.
10. Nyman RS, Cappelen-Smith J, Brismar J, et al. Yield and complications in ultrasound-guided biopsy of abdominal lesions. Comparison of fine-needle aspiration biopsy and 1.2-mm needle core biopsy using an automated biopsy gun. Acta Radiol. 1995;36:485-490.
11. Hugosson CO, Nyman RS, Cappelen-Smith JM, et al. Ultrasound-guided biopsy of abdominal and pelvic lesions in children: a comparison between fine-needle aspiration and 1.2 mm-needle core biopsy. Pediatr Radiol. 1999;29:31-36.
12. Moulton JS, Moore PT. Coaxial percutaneous biopsy technique with automated biopsy devices: value in improving accuracy and negative predictive value. Radiology. 1993;186:515-522.
13. Miller DA, Carrasco CH, Katz RL, et al. Fine needle aspiration biopsy: the role of immediate cytologic assessment. AJR Am J Roentgenol. 1986;147:155-158.
14. Silverman JF, Finley JL, O'Brien KF, et al. Diagnostic accuracy and role of immediate interpretation of fine needle aspiration biopsy specimens from various sites. Acta Cytol. 1989;33:791-796.
15. Logrono R, Kurtycz DF, Sproat IA, et al. Multidisciplinary approach to deep-seated lesions requiring radiologically-guided fine-needle aspiration. Diagn Cytopathol. 1998;18:338-342.
16. Bell DA, Carr CP, Szyfelbein WM. Fine needle aspiration cytology of focal liver lesions: results obtained with examination of both cytologic and histologic preparations. Acta Cytol. 1986;30:397-402.
17. Chiu KW, Chang-Chien CS, Chen L, et al. Ultrasonically-guided needle aspiration with preparation of cell blocks in the diagnosis of liver tumors. Hepatogastroenterology. 1994;41:30-33.
18. Kern WH, Haber H. Fine needle aspiration minibiopsies. Acta Cytol. 1986;30:403-408.
19. Hahn PF, Eisenberg PJ, Pitman MB, et al. Cytopathologic touch preparations (imprints) from core needle biopsies: accuracy compared with that of fine-needle aspirates. AJR Am J Roentgenol. 1995;165:1277-1279.
20. Zardawi IM. Fine needle aspiration cytology vs core biopsy in a rural setting. Acta Cytol. 1998;42:883-887.
21. Shak K, Goodman Z, Stocker J, eds. Tumors of the Liver and Intrahepatic Bile Ducts. 3rd series. Vol 31. Washington, DC: AFIP; 2001.
22. Dey P, Amir T, Jogai S, et al. Fine-needle aspiration cytology of metastatic transitional cell carcinoma. Diagn Cytopathol. 2005;32:226-228.
23. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36:415-420.
24. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54:243-250.
25. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.
26. Tot T. The role of cytokeratins 20 and 7 and estrogen receptor analysis in separation of metastatic lobular carcinoma of the breast and metastatic signet ring cell carcinoma of the gastrointestinal tract. APMIS. 2000;108:467-472.
27. Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology. 1996;29:233-240.
28. Yim H, Jin YM, Shim C, et al. Gastric metastasis of mammary signet ring cell carcinoma: a differential diagnosis with primary gastric signet ring cell carcinoma. J Korean Med Sci. 1997;12:256-261.
29. Nash JW, Morrison C, Frankel WL. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver. Arch Pathol Lab Med. 2003;127:1591-1595.
30. Pitman MB. Fine needle aspiration biopsy of the liver: principal diagnostic challenges. Clin Lab Med. 1998;18:483-506, vi.
31. Lack EE, Mulvihill JJ, Travis WD, et al. Adrenal cortical neoplasms in the pediatric and adolescent age group: clinicopathologic study of 30 cases with emphasis on epidemiological and prognostic factors. Pathol Annu. 1992;27(Pt 1):1-53.
32. Serrano R, Rodriguez-Peralto JL, Santos-Briz A, et al. Fine needle aspiration cytology of metastatic hepatic adrenocortical carcinoma mimicking hepatocellular carcinoma: a case report. Acta Cytol. 2001;45:768-770.
33. Orchard G. Evaluation of melanocytic neoplasms: application of a pan-melanoma antibody cocktail. Br J Biomed Sci. 2002;59:196-202.
34. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54:196-200.
35. Dong HY, Harris NL, Preffer FI, et al. Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry. Mod Pathol. 2001;14:472-481.
36. Moriarty AT, Wiersema L, Snyder W, et al. Immunophenotyping of cytologic specimens by flow cytometry. Diagn Cytopathol. 1993;9:252-258.
37. Liu K, Mann KP, Vitellas KM, et al. Fine-needle aspiration with flow cytometric immunophenotyping for primary diagnosis of intra-abdominal lymphomas. Diagn Cytopathol. 1999;21:98-104.
38. Wieczorek TJ, Faquin WC, Rubin BP, et al. Cytologic diagnosis of gastrointestinal stromal tumor with emphasis on the differential diagnosis with leiomyosarcoma. Cancer. 2001;93:276-287.
39. Loy TS, Phillips RW, Linder CL. A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases. Arch Pathol Lab Med. 2002;126:170-172.
40. Shin SJ, Hoda RS, Ying L, et al. Diagnostic utility of the monoclonal antibody A103 in fine-needle aspiration biopsies of the adrenal. Am J Clin Pathol. 2000;113:295-302.
41. Renshaw AA, Granter SR. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. Mod Pathol. 1998;11:1160-1164.
42. Jalali M, Krishnamurthy S. Comparison of immunomarkers for the identification of adrenocortical cells in cytology specimens. Diagn Cytopathol. 2005;33:78-82.
43. Jorda M, De MB, Nadji M. Calretinin and inhibin are useful in separating adrenocortical neoplasms from pheochromocytomas. Appl Immunohistochem Mol Morphol. 2002;10:67-70.
44. Zhang PJ, Genega EM, Tomaszewski JE, et al. The role of calretinin, inhibin, melan-A, BCL-2, and C-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Mod Pathol. 2003;16:591-597.
45. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210.
46. Beham A, Ratschek M, Zatloukal K, et al. Immunohistochemical analysis of 42 renal cell carcinomas and one oncocytoma with mono- and polyclonal antibodies against vimentin and cytokeratin. Verh Dtsch Ges Pathol. 1989;73:392-395.
47. Medeiros LJ, Gelb AB, Weiss LM. Low-grade renal cell carcinoma: a clinicopathologic study of 53 cases. Am J Surg Pathol. 1987;11:633-642.
48. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28:69-76.
49. Borscheri N, Roessner A, Rocken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol. 2001;25:1297-1303.
50. Johnson DE, Herndier BG, Medeiros LJ, et al. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol. 1988;12:187-197.
51. Balaton AJ, Nehama-Sibony M, Gotheil C, et al. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections. J Pathol. 1988;156:305-310.
52. Porcell AI, De Young BR, Proca DM, et al. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol. 2000;13:773-778.
53. Proca DM, Niemann TH, Porcell AI, et al. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver: report of findings and review of other utilized markers. Appl Immunohistochem Mol Morphol. 2000;8:120-125.
54. Fan Z, van de Rijn M, Montgomery K, et al. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137-144.
55. Lau SK, Prakash S, Geller SA, et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33:1175-1181.
56. Morrison C, Marsh W Jr, Frankel WL. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol. 2002;15:1279-1287.
57. Chu PG, Ishizawa S, Wu E, et al. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol. 2002;26:978-988.
58. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expressions of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem. 1995;3:99-107.
59. Maeda T, Kajiyama K, Adachi E, et al. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol. 1996;9:901-909.
60. Maeda T, Takenaka K, Taguchi K, et al. Adenosquamous carcinoma of the liver: clinicopathologic characteristics and cytokeratin profile. Cancer. 1997;80:364-371.
61. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer. 1999;85:171-177.
62. Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer. 2001;92:2727-2732.
63. Tot T, Samii S. The clinical relevance of cytokeratin phenotyping in needle biopsy of liver metastasis. APMIS. 2003;111:1075-1082.
64. Lau SK, Desrochers MJ, Luthringer DJ. Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol. 2002;15:538-542.
65. Saad RS, Cho P, Silverman JF, et al. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol. 2004;122:421-427.
66. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21:391-400.
67. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116:319-325.
68. Kim MA, Lee HS, Yang HK, et al. Cytokeratin expression profile in gastric carcinomas. Hum Pathol. 2004;35:576-581.
69. Goldstein NS, Bassi D. Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas: percentage of positivity and distribution is affected by the cut-point threshold. Am J Clin Pathol. 2001;115:695-702.
70. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8-16.
71. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002;10:97-102.
72. Chhieng DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer. 2001;93:330-336.
73. Simsir A, Wei XJ, Yee H, et al. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2004;121:350-357.
74. Hecht JL, Pinkus JL, Weinstein LJ, et al. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol. 2001;116:483-488.
75. O'Connell FP, Wang HH, Odze RD. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med. 2005;129:338-347.
76. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
77. Fiel MI, Cernaianu G, Burstein DE, et al. Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol. 1996;40:637-641.
78. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol. 1989;20:281-287.
79. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163.
80. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33:1136-1140.
81. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
82. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683-687.
83. Lagendijk JH, Mullink H, van Diest PJ, et al. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin: comparison between a statistical and an intuitive approach. J Clin Pathol. 1999;52:283-290.
84. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998;29:491-497.
85. Li MK, Folpe AL. CDX-2, a new marker for adenocarcinoma of gastrointestinal origin. Adv Anat Pathol. 2004;11:101-105.
86. Raspollini MR, Amunni G, Villanucci A, et al. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases. Appl Immunohistochem Mol Morphol. 2004;12:127-131.
87. Saad RS, Essig DL, Silverman JF, et al. Diagnostic utility of CDX-2 expression in separating metastatic gastrointestinal adenocarcinoma from other metastatic adenocarcinoma in fine-needle aspiration cytology using cell blocks. Cancer. 2004;102:168-173.
88. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol. 2000;17:184-193.
89. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: a diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997;107:12-19.
90. Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2001;195:41-52.
91. Yeang CH, Ramaswamy S, Tamayo P, et al. Molecular classification of multiple tumor types. Bioinformatics. 2001;17(suppl 1):S316-S322.
92. Bloom G, Yang IV, Boulware D, et al. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol. 2004;164:9-16.
93. Alaiya AA, Franzen B, Hagman A, et al. Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int J Cancer. 2002;98:895-899.
94. Ellis M, Davis N, Coop A, et al. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res. 2002;8:1155-1166.
95. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003;9:2406-2415.
96. Sotiriou C, Powles TJ, Dowsett M, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002;4:R3. Epub 2002 Mar 20.
97. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003;97:2960-2971.
98. Assersohn L, Gangi L, Zhao Y, et al. The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res. 2002;8:794-801.
99. Dunmire V, Wu C, Symmans WF, et al. Increased yield of total RNA from fine-needle aspirates for use in expression microarray analysis. Biotechniques. 2002;33:890-892, 894, 896.
100. Centeno BA, Enkemann SA, Coppola D, et al. Classification of human tumors using gene expression profiles obtained after microarray analysis of fine-needle aspiration biopsy samples. Cancer. 2005;105:101-109.
101. Fetsch PA, Simone NL, Bryant-Greenwood PK, et al. Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol. 2002;118:870-876.